December 1st 2021
Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.
April 8th 2021
Edward B. Garon, MD, discusses immunotherapy treatment considerations for patients with non–small cell lung cancer.
July 24th 2019
Edward B. Garon, MD, MS, discusses the KEYNOTE-001 study, which examined the 5-year long-term overall survival in patients with non–small cell lung cancer treated with pembrolizumab.
February 11th 2016
The role of immunotherapy is emerging as an effective, and in some cases, dramatic treatment in the non-small cell lung cancer landscape.